Gastrointestinal Cancer Clinical Trials & Research at Providence Medical Group
Providence Medical Group is currently enrolling patients for the following
Gastrointestinal studies:
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab
vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic
Cancer Patients with DNA Damage Repair Defects (SWOG S2001)
Treatment agent: Olaparib +/- Pembrolizumab
Physician:
Yao Yao Pollock, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
https://clinicaltrials.gov/study/NCT04548752
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center Santa Rosa, CA
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and
Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine
Tumors (SWOG S2104)
Treatment agent: Capecitabine and Temozolimide
Physician:
Yao Yao Pollock, MD
Study Coordinator: Beatrice Becker //
beatrice.becker@providence.org // 707-932-5164
Study Resources:
https://www.clinicaltrials.gov/study/NCT05040360
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center Santa Rosa, CA
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in
Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (NRG-GI005 COBRA)
Treatment agent: Screening: circulating tumor DNA blood test
Physician:
Yao Yao Pollock, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
https://clinicaltrials.gov/study/NCT04068103
Sponsor: National Cancer Institute (NCI) / NRG Oncology Clinical Trials
Location: Providence Cancer Center Santa Rosa, CA